VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2020 | ENDURANCE trial: KRd versus VRd for initial therapy of NDMM

Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses the results of the ENDURANCE trial (NCT01863550), a Phase III study of bortezomib, lenalidomide, and dexamethasone (VRd) compared to carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (NDMM). Dr Kumar reveals that VRd remains the standard triplet induction regimen in standard and intermediate-risk NDMM. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter